Literature DB >> 16804106

Sustained renal interstitial macrophage infiltration following chronic angiotensin II infusions.

Yuri Ozawa1, Hiroyuki Kobori, Yuki Suzaki, L Gabriel Navar.   

Abstract

Chronic angiotensin (ANG) II infusions into rats lead to augmented intrarenal levels of ANG II and inflammatory factors, impaired renal function, and progressive hypertension. Residual effects persist after cessation of ANG II infusions, as manifested by a hypertensive response to high-salt intake. This study was performed to determine the residual cytokines and chemokines following the cessation of ANG II infusion. Male Sprague-Dawley rats, maintained on a normal diet, received either a sham operation or continuous ANG II infusion (120 ng/min) subcutaneously via minipumps. The ANG II-infused rats were further subdivided into three subgroups. Minipumps were removed on day 12 with subsequent harvesting of kidneys at 0, 3, and 6 days after cessation of ANG II infusion. After 12 days of ANG II infusion, systolic blood pressure, interstitial fibrosis, preglomerular hypertrophy, and interstitial macrophage infiltration were significantly enhanced compared with the shams. By 3 days following the cessation of ANG II infusion, systolic blood pressure was normalized; however, interstitial fibrosis and preglomerular hypertrophy were still present. Furthermore, increased interstitial macrophage infiltration was still present 6 days after cessation of ANG II infusion. Importantly, augmented mRNA levels of monocyte chemotactic protein (MCP)-1 (1.55 +/- 0.15 vs. 1.00 +/- 0.13, relative ratio) and transforming growth factor (TGF)-beta(1) (1.52 +/- 0.16 vs. 1.00 +/- 0.08) persisted 6 days after the withdrawal of ANG II infusion (1.60 +/- 0.20 for MCP-1 and 1.43 +/- 0.17 for TGF-beta(1)). Thus, the ANG II-induced activation of MCP-1 and TGF-beta(1) is sustained and may account for the persistent effect of chronic ANG II infusions on interstitial macrophage infiltration, suggesting a possible mechanism for the development of salt sensitivity in ANG II-dependent hypertension.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16804106      PMCID: PMC2001287          DOI: 10.1152/ajprenal.00059.2006

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  64 in total

Review 1.  TGF-beta in kidney fibrosis: a target for gene therapy.

Authors:  W A Border; N A Noble
Journal:  Kidney Int       Date:  1997-05       Impact factor: 10.612

2.  TGF-beta1 stimulates monocyte chemoattractant protein-1 expression in mesangial cells through a phosphodiesterase isoenzyme 4-dependent process.

Authors:  Jingfei Cheng; Montserrat M Diaz Encarnacion; Gina M Warner; Catherine E Gray; Karl A Nath; Joseph P Grande
Journal:  Am J Physiol Cell Physiol       Date:  2005-06-01       Impact factor: 4.249

3.  Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice.

Authors:  F N Ziyadeh; B B Hoffman; D C Han; M C Iglesias-De La Cruz; S W Hong; M Isono; S Chen; T A McGowan; K Sharma
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

4.  Renal cortical vasoconstriction contributes to development of salt-sensitive hypertension after angiotensin II exposure.

Authors:  Martha Franco; Edilia Tapia; José Santamaría; Ignacio Zafra; Romeo García-Torres; Katherine L Gordon; Héctor Pons; Bernardo Rodríguez-Iturbe; Richard J Johnson; Jaime Herrera-Acosta
Journal:  J Am Soc Nephrol       Date:  2001-11       Impact factor: 10.121

5.  Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions.

Authors:  N Sanderson; V Factor; P Nagy; J Kopp; P Kondaiah; L Wakefield; A B Roberts; M B Sporn; S S Thorgeirsson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

6.  A mouse model of angiotensin II slow pressor response: role of oxidative stress.

Authors:  Noritaka Kawada; Enyu Imai; Alexsander Karber; William J Welch; Christopher S Wilcox
Journal:  J Am Soc Nephrol       Date:  2002-12       Impact factor: 10.121

7.  Circulating leukocyte counts, activation, and degranulation in Dahl hypertensive rats.

Authors:  K Shen; F A DeLano; B W Zweifach; G W Schmid-Schönbein
Journal:  Circ Res       Date:  1995-02       Impact factor: 17.367

8.  Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction.

Authors:  Vanesa Esteban; Oscar Lorenzo; Mónica Rupérez; Yusuke Suzuki; Sergio Mezzano; Julia Blanco; Mathias Kretzler; Takeshi Sugaya; Jesús Egido; Marta Ruiz-Ortega
Journal:  J Am Soc Nephrol       Date:  2004-06       Impact factor: 10.121

9.  Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.

Authors:  D E Vaughan; S A Lazos; K Tong
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

10.  Tumor necrosis factor activates angiotensinogen gene expression by the Rel A transactivator.

Authors:  A R Brasier; J Li; K A Wimbish
Journal:  Hypertension       Date:  1996-04       Impact factor: 10.190

View more
  86 in total

1.  Angiotensin AT₂ receptor stimulation inhibits early renal inflammation in renovascular hypertension.

Authors:  Luis C Matavelli; Jiqian Huang; Helmy M Siragy
Journal:  Hypertension       Date:  2010-12-28       Impact factor: 10.190

2.  Addition of angiotensin II type 1 receptor blocker to CCR2 antagonist markedly attenuates crescentic glomerulonephritis.

Authors:  Maki Urushihara; Naro Ohashi; Kayoko Miyata; Ryousuke Satou; Omar W Acres; Hiroyuki Kobori
Journal:  Hypertension       Date:  2011-01-31       Impact factor: 10.190

3.  A novel role for type 1 angiotensin receptors on T lymphocytes to limit target organ damage in hypertension.

Authors:  Jian-dong Zhang; Mehul B Patel; Young-Soo Song; Robert Griffiths; James Burchette; Phillip Ruiz; Matthew A Sparks; Ming Yan; David N Howell; Jose A Gomez; Robert F Spurney; Thomas M Coffman; Steven D Crowley
Journal:  Circ Res       Date:  2012-04-24       Impact factor: 17.367

Review 4.  Monocytes as immune targets in arterial hypertension.

Authors:  Philip Wenzel
Journal:  Br J Pharmacol       Date:  2018-07-14       Impact factor: 8.739

Review 5.  Immunologic Effects of the Renin-Angiotensin System.

Authors:  Steven D Crowley; Nathan P Rudemiller
Journal:  J Am Soc Nephrol       Date:  2017-02-01       Impact factor: 10.121

6.  Interleukin-6 inhibition attenuates hypertension and associated renal damage in Dahl salt-sensitive rats.

Authors:  Shireen Hashmat; Nathan Rudemiller; Hayley Lund; Justine M Abais-Battad; Scott Van Why; David L Mattson
Journal:  Am J Physiol Renal Physiol       Date:  2016-06-08

Review 7.  Macrophage heterogeneity and renin-angiotensin system disorders.

Authors:  Mark D Wright; Katrina J Binger
Journal:  Pflugers Arch       Date:  2017-02-08       Impact factor: 3.657

8.  Purinergic receptors contribute to early mesangial cell transformation and renal vessel hypertrophy during angiotensin II-induced hypertension.

Authors:  Miguel L Graciano; Akira Nishiyama; Keith Jackson; Dale M Seth; Rudy M Ortiz; Minolfa C Prieto-Carrasquero; Hiroyuki Kobori; L Gabriel Navar
Journal:  Am J Physiol Renal Physiol       Date:  2007-11-07

9.  ROCK/NF-κB axis-dependent augmentation of angiotensinogen by angiotensin II in primary-cultured preglomerular vascular smooth muscle cells.

Authors:  Kayoko Miyata; Ryousuke Satou; Weijian Shao; Minolfa C Prieto; Maki Urushihara; Hiroyuki Kobori; L Gabriel Navar
Journal:  Am J Physiol Renal Physiol       Date:  2014-01-15

10.  Increased angiotensinogen expression, urinary angiotensinogen excretion, and tissue injury in nonclipped kidneys of two-kidney, one-clip hypertensive rats.

Authors:  Weijian Shao; Kayoko Miyata; Akemi Katsurada; Ryousuke Satou; Dale M Seth; Carla B Rosales; Minolfa C Prieto; Kenneth D Mitchell; L Gabriel Navar
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.